S&W to acquire Irish accountancy firm Beechwood Partners
As per the terms of the deal, 35 employees and partners from Beechwood Partners integrate into S&W's operations in Ireland, which currently has a workforce of more than 80 at its Sandyford location.
This transaction represents S&W's inaugural acquisition as an independent entity following its establishment as a professional services group in March 2025, with support from Apax Partners.
With origins tracing back to Smith & Williamson, founded in 1881, S&W employs more than 1,850 individuals and has in excess of 120 partners across the UK and Ireland.
The firm provides a variety of services in the accountancy mid-market, including corporate tax advice, assurance, business services, and a range of advisory and digital solutions encompassing recovery and restructuring, transaction services, and forensic advice.
S&W CEO Andrew Wilkes said: 'I'm delighted to welcome the team from Beechwood Partners to S&W in our first acquisition as a stand-alone group as we play out our drive to accelerate growth.
'Beechwood Partners is a highly respected business that shares our partner-led approach of developing long-standing relationships with clients and adding meaningful value.
'This deal strengthens our position in Ireland and forms part of our growth strategy of acquiring high-quality accountancy firms with complementary expertise.'
The acquisition of Beechwood Partners will allow S&W to expand its offerings in private client tax solutions in Ireland, as well as enhance its business outsourcing and business tax services.
Beechwood Partners partner Weston Allen said: 'Having grown Beechwood Partners as a successful independent business over the past 20 years, the timing is right to pursue an exciting next chapter by partnering with a large, well-established firm.
'Having considered a number of options, S&W has given us every confidence that this deal will empower us with the necessary infrastructure and support to improve and expand our service offerings while continuing to grow our business and service our clients' needs.'
"S&W to acquire Irish accountancy firm Beechwood Partners" was originally created and published by International Accounting Bulletin, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Why Coty Stock Is Plummeting Today
Key Points Coty beat Wall Street's sales target in fiscal Q4, but the business posted an unexpected loss. Margin pressures have investors worried about the company's earnings outlook. Coty is guiding for another substantial sales decline in the current quarter, and the margins picture is concerning. 10 stocks we like better than Coty › Coty (NYSE: COTY) stock is getting crushed in Thursday's trading. The beauty products and fragrance company's share price was down 22.3% as of 2 p.m. ET. amid the backdrop of a 0.4% loss for the S&P 500 (SNPINDEX: ^GSPC). After the market closed yesterday, Coty published results for the fourth quarter of its last fiscal year, which ended June 30. While the company posted sales that topped Wall Street's expectations, earnings fell short of the market's target. Making matters worse, management issued guidance that suggested more pain could be on the horizon. Coty stock crashes on big earnings miss Coty reported a non-GAAP (generally accepted accounting principles) adjusted loss of $0.05 per share on sales of $1.25 billion. While the company's sales performance topped the average Wall Street analyst estimate by $40 million, its earnings performance fell short of the consensus target by $0.07 per share. With the business posting an unexpected loss and sales declining 8.1% year over year in the quarter, the consumer goods specialist is looking significantly weaker coming out of its latest quarterly report. What's next for Coty? While Coty is seeing some growth in its prestige-fragrance product category, the company's latest business update didn't arrive with much for investors to be excited about. Coty reiterated its guidance for like-for-like (LFL) sales to improve over the levels seen last quarter in the current fiscal year, but management said that it expects an LFL sales decline between 6% and 8% in fiscal Q1. With worse-than-expected margins leading to an unexpected loss last quarter and guidance for another big sales decline in the current quarter, Coty's earnings outlook has taken a substantial turn for the worse. Should you invest $1,000 in Coty right now? Before you buy stock in Coty, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Coty wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,624!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,117!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Coty Stock Is Plummeting Today was originally published by The Motley Fool Sign in to access your portfolio
CNBC
28 minutes ago
- CNBC
The S&P 500 heads for a fifth day of declines, but drug stocks are a bright spot
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks are trading lower Thursday. The S & P 500 , in particular, is on pace for its fifth straight loss, wiping out all of August's gains. The rotation out of momentum-driven winners and stocks with lofty price-to-earnings multiples — the dominant market story of the week — isn't as pronounced Thursday, with stocks like Club name GE Vernova and Palantir holding up better on a relative basis. However, the influential "Magnificent Seven" cohort is mostly weaker, which explains why the traditional market-cap weighted S & P 500 is slightly underperforming the Invesco S & P 500 equal-weight ETF , known as the RSP. Holding up : The health-care sector is putting together a solid few days despite the broader market weakness. The group, which is still one of the worst performing sectors this year, came to life last week thanks to a surge in the beleaguered UnitedHealth Group on news that Berkshire Hathaway purchased a stake in managed care giant during the second quarter. Club name Eli Lilly also start to rebound from its post-earnings sell-off, giving the sector a lift. Fast-forward to Thursday, and pharma stocks are helping push the health-care group higher, and those rallies are linked to some better-than-feared trade news. According to the updated trade agreement framework between the United States and the European Union, branded pharmaceuticals imported from the EU will face a 15% tariff rate. Uncertainty over the Trump administration's Section 232 sectoral tariffs on pharmaceutical imports hasn't gone away, but 15% is much more manageable than some of the triple-digit threats President Donald Trump has previously floated. Europe is a popular place for drug manufacturing. Shares of both Bristol Myers Squibb and Eli Lilly were higher on Thursday as investors digested the tariff developments. With Thursday's move, Lilly shares are down less than 5% from where they closed the day before its disappointing obesity pill data sent the stock plunging 14% in a single session. Up next: Zoom Communications , Workday , Intuit and Ross Stores report after the closing bell on Thursday. Ross Stores is a rival of Club stock TJX Companies , which reported its own strong set of results Wednesday morning. Meanwhile, Costco peer BJ's Wholesale reports on Friday. However, the main event of the day will be Fed Chair Jerome Powell's speech at annual Jackson Hole Economic Symposium. It starts at 10 a.m. ET and will be a market-moving event. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Yahoo
an hour ago
- Yahoo
My Top Dividend-Paying, Deep-Value Stock to Buy in August
Key Points Pfizer offers the highest forward dividend yield in the healthcare sector. The stock trades at an exceptionally attractive valuation. Pfizer faces some challenges but should continue to survive and thrive as it has for 176 years. 10 stocks we like better than Pfizer › What's better than a stock that pays great dividends? How about one that's also a bargain? Granted, most strong dividend stocks aren't available at a discount in the current high-flying market. However, that doesn't mean you can't find them at all. I can think of several dividend-paying, deep-value stocks to buy in August. One stock stands at the top of my list: pharmaceutical giant Pfizer (NYSE: PFE). Pfizer's juicy dividend Pfizer's forward dividend yield currently stands at 6.86%. This yield is so attractive that I wondered if it's the highest of any healthcare stock. It is (or was recently, anyway). As of Aug. 19, 2025, Pfizer's forward dividend yield was the juiciest in the healthcare sector. The big drugmaker's dividend track record is impressive, too. Pfizer has paid 347 consecutive quarterly dividends. The company has increased its dividend for 16 consecutive years. Can Pfizer keep the dividends flowing and growing? I think it can. So does the company's management team. CFO David Denton reiterated in Pfizer's second-quarter earnings call that the dividend program remains first on the drugmaker's capital allocation priorities, stating, "Our strategy consists of maintaining and growing our dividend over time." Sure, Pfizer's dividend payout ratio of around 90% is higher than I'd like. However, the pharmaceutical company's earnings continue to grow. Pfizer even recently raised its full-year earnings guidance. It's also on track to cut costs by around $7.2 billion by the end of 2027, which will further improve the bottom line and the payout ratio. A tremendous value Let's shift gears to discuss Pfizer's tremendous value. The stock's forward price-to-earnings (P/E) ratio is only 8.3. That's a fraction of the S&P 500's forward earnings multiple of 22.8. It's also well below the S&P 500 healthcare sector's average forward P/E of 16.5. One question comes to mind, though: Is Pfizer a value trap? After all, the drugmaker faces a patent cliff with several of its top-selling products losing patent exclusivity over the next few years. The list includes blood thinner Eliquis, which generated nearly $7.6 billion for Pfizer last year, and breast cancer drug Ibrance, which raked in almost $4.4 billion in sales. I think Pfizer is in a better position than meets the eye to navigate its patent cliff. The company has several new products with strong growth prospects, notably including migraine drug Nurtec ODT, RSV vaccine Abrysvo, and multiple myeloma drug Elrexfio. Pfizer's pipeline also features 108 candidates, with 28 late-stage programs and four awaiting regulatory approvals. Wall Street seems to agree that Pfizer isn't a value trap. The consensus 12-month price target reflects an upside potential of over 13%. Pfizer's price-to-earnings-to-growth (PEG) ratio, which is based on five-year earnings growth projections of analysts surveyed by LSEG, is a low 0.86. This PEG ratio suggests that analysts aren't overly concerned about Pfizer's growth prospects, even with multiple drugs losing exclusivity. Some risks Pfizer does face some risks. Although I believe it will weather the patent cliff relatively well, the losses of exclusivity make the company more dependent on the success of its new drugs and pipeline programs. Sometimes, new drugs don't perform as well as expected. Pipeline candidates can also sometimes flop in clinical trials. President Trump's threatened pharmaceutical tariffs could negatively impact Pfizer. So could his administration's push to implement "most-favored-nation" drug pricing, which aims to tie U.S. drug prices to the lowest prices paid by other developed nations. Again, though, I think Pfizer will survive and thrive -- just as it has for 176 years. For investors seeking high dividend yields and deep value, I view Pfizer as the best pick on the market right now. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. My Top Dividend-Paying, Deep-Value Stock to Buy in August was originally published by The Motley Fool Sign in to access your portfolio
